O slideshow foi denunciado.
Utilizamos seu perfil e dados de atividades no LinkedIn para personalizar e exibir anúncios mais relevantes. Altere suas preferências de anúncios quando desejar.

Management of acute graft-versus-host disease

5.054 visualizações

Publicada em

Publicada em: Tecnologia, Saúde e medicina
  • Holistic Candida Secrets, Eliminate Yeast Infection Fast. Candida cure e-book reveals all ➤➤ http://ishbv.com/index7/pdf
    Tem certeza que deseja  Sim  Não
    Insira sua mensagem aqui
  • How I Cured My Candida, Life-long Sufferer Discovers, Powerful Secret To Yeast Infection Freedom ■■■ http://ishbv.com/index7/pdf
    Tem certeza que deseja  Sim  Não
    Insira sua mensagem aqui
  • Seja a primeira pessoa a gostar disto

Management of acute graft-versus-host disease

  1. 1. Management of acute graft-versus-host disease Andrea Bacigalupo Divisione Ematologia e Trapianto di Midollo, Ospedale San Martino, Genova, Italy Summary Acute graft-versus-host disease (GvHD) is a frequent compli- cation of allogeneic haemopoietic stem cell transplantation (HSCT) and donor lymphocyte infusions (DLI). Its incidence and severity depends on several factors, such as prophylaxis method, donor/recipient matching, intensity of the condition- ing regimen and composition of the graft. Significant progress has been made in recent years in understanding the pathogen- esis of the disease, and some of these advances have been translated into clinical trials. First-line treatment of acute GvHD is based on corticosteroids, and produce sustained responses in 50–80% of patients depending on the initial severity. Non- responders are offered second-line therapy, with combinations of immunosuppressive agents, but 1-year survival is 30% in most large trials. New strategies explored include infusion of expanded mesenchymal stem cells (MSC), down regulation of antigen-presenting cells (APC) and suicide gene transduced T cells. Acute GvHD is complicated by severe immunodefi- ciency causing life-threatening infections. To date, GvHD has not been differentiated from the graft-versus-leukaemia effect. The present review will discuss some of these aspects. Keywords: graft-versus-host disease, haemopoietic stem cell transplantation, donor lymphocyte infusion, immunosuppres- sive therapy, mesenchymal stem cells. Do we understand the pathogenesis of GvHD? Although the pathogenesis of graft-versus-host disease (GvHD) is not the aim of the present review, a few words are warranted: indeed some of the recent advances in understanding cellular and cytokine mechanisms leading to GvHD have been useful in the clinic. GvHD is thought to be caused by donor T cells reacting against host allo-antigens: this may well be the case, but the mechanism underlying such immune reaction are quite complex (Teshima & Ferrara, 2002a). The early work of Ferrara and coworkers showed that inflammatory cytokines play a crucial role in the initial, amplification and cytotoxic phases of the disease (reviewed in Ferrara, 2002). Unfortu- nately, it seems that inactivation of cytokines, such as tumour necrosis factor (TNF) is not sufficient per se, and some initial success has come at the expense of increased infectious complications (Marty et al, 2003). More recently, the presen- tation of target antigens by host antigen presenting cells (APC) has been shown to be crucial for the initiation and develop- ment of acute GvHD (Shlomchik et al, 1999): in an early experiment, Shlomchik showed that mice with APC that were unable to present class I-restricted peptides (grafted from b2 knock-out), but that expressed class I on target tissues, were unable to develop acute GvHD (Shlomchik et al, 1999). Therefore host APC participate in activating donor T cells to kill host cells and the age of host APC seems relevant (in keeping with the notion that older patients have more GvHD) (Ordemann et al, 2002). The presentation of host antigens by host APC can be further enhanced by host gamma/delta T cells, as recently shown in the mouse (Maeda et al, 2005). The interplay of APC, T cells and cytokines is such that, in a mouse transplant model – with mismatch only between donor T cells and host APC, but not between donor and host gut-donor T cells still efficiently killed host gut cells, suggesting that tissue destruction can be achieved with a by-stander effect (Teshima et al, 2002b). Finally, attention has also been given to cellular interplay leading to tolerance: Two reports merit mentioning. Mc Donald et al (2005) dealt with cytokine-expanded myeloid precursors regulating APC and promoting tolerance through interleukin (IL)-10-producing regulatory T cells. Lan et al (2001) looked directly at regulatory T cells (TREGS): mice given lymphoid radiation and antithymocyte globulin (ATG) were depleted of most T cells, but not of NK 1.1 T cells, and became resistant to GvHD. The Stanford group has brought this in to the clinic: they have shown that the combination of total lymphoid radiation (TLI) and ATG depletes host T cells with the exception of CD4+ CD25+ TREGS: when allografted these patients showed little or no GvHD, suggesting a regulatory role of host TREGS on donor incoming alloreactive T cells (Lowsky et al, 2005). Do we understand the pathogenesis of GvHD? Not fully: however, we have become aware of the complexity of the disease, and we have learned to take advantage of some developments in the lab. Further studies in the animal model Correspondence: Dr A Bacigalupo, Divisione di Ematologia II, Ospedale San Martino, Piazzale Rosanna Benzi, 10, Genova, Italy. E-mail: andrea.bacigalupo@hsanmartino.it review ª 2007 The Author Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98 doi:10.1111/j.1365-2141.2007.06533.x
  2. 2. will possibly bring further advances in the clinic. Tolerance may be achieved in more than one way. Can acute GvHD be accurately graded? The original grading system for acute GvHD was proposed by Glucksberg et al (1974) and identified five categories of patients (grades 0, I, II, III, IV). It is known as the Glucksberg-Seattle criteria (GSC) and it is based on the degree of skin, liver and gut involvement (skin rash, total serum bilirubin and diarrhoea volume), together with a subjective assessment of clinical status. The GSC have been widely used for 30 years and correlate well with transplant-related mortal- ity (TRM): a recent analysis of 4174 human leucocyte antigen (HLA)-identical sibling transplants for chronic myeloid leuk- aemia (CML) in first chronic phase showed that early and long-term outcome is influenced by severity of acute GvHD as identified by the classic GSC (Gratwohl et al, 2002). Indeed at 3 years survival was 74%, 74%, 64%, 37% and 10% for patients with acute GvHD grades 0, I, II, III and IV respectively. In 1997, the International Bone Marrow Trans- plant Registry (IBMTR) designed a staging system from a large data set of adult patients receiving an HLA identical sibling BMT (Rowlings et al, 1997): the IBMTR Severity Index regroups patients into five categories (0, A, B, C, D) based on differences in TRM with a significance level of 0Æ05. Despite good correlation of the IBMTR index with outcome, the classic GSC is still used in most centres. Recently, we have shown that the GSC can be further implemented by adding platelet counts on day+50: patients with grade II acute GvHD and a platelet count of less than 50 · 109 /l had significantly higher TRM when compared to patients with grade II GvHD and platelets ‡50 · 109 /l (Dominietto et al, 2001). Can we score GvHD? Not well enough: however the classic GSC is still here after three decades, suggesting it is clinically useful. The use of laboratory values, such as platelet counts and cholinesterase, or other clinical parameters (Lee et al, 2005) may further improve our ability to predict the outcome of patient undergoing an allogeneic transplant, and perhaps to modify treatment accordingly. Can GvHD be prevented? HLA matching HLA matching between donor and recipient is one of the most powerful predictors of GvHD, together with other factors such as age, donor/recipient sex match. Other supportive measures, such as a sterile environment have been shown to protect against GvHD both in animals and humans. Therefore using a young-HLA matched, male donor, in a protected sterile environment, is a very effective way of having little GvHD. However, HLA-matched related donors are less common, at least in Europe and the USA, and there is greater use of unrelated donors or related HLA-mismatched donors. Thus the question really is: can GvHD be prevented in less favourable situations? T cell depletion ex-vivo Removal of T cells from the stem cell suspension, referred to as T cell depletion (TCD) ex-vivo, was very popular in the 1980s, but its use has declined over the past decade: this is because survival, disease-free survival and transplant mortality were not reduced, in the setting of HLA-matched grafts, when compared with conventional unmanipulated transplants (Mar- mont et al, 1991). One situation in which ex vivo-TCD is essential, is 3 loci mismatched transplants: in this setting T cell depletion must be thorough and one should not infuse more than 5 · 104 CD3+ cells/kg of recipients weight, as shown by Aversa et al (1998). TCD should be performed in a centre with a dedicated programme, where different forms of T cell removal can be explored, including physical and immunolo- gical TCD (Martin & Kernan, 1997; Aversa et al, 1998). T cell depletion in vivo Treatment of the patient with T cell antibodies before the transplant, in vivo-TCD, has a double target: it reduces the host immune response, favouring engraftment, and downregulates donor T cells, because the antibody is still in circulation at the time of transplant, and thus prevents GvHD (Hows et al, 1993; Holler et al, 1998; Baurmann et al, 1999; Zander et al, 1999; Byrne et al, 2000; Finke et al, 2000). In vivo-TCD is indicated in programmes involving alternative donor transplants, and is used in many, but not all centres performing unrelated donor grafts (Hows et al, 1993; Hansen et al, 1998; Holler et al, 1998; Baurmann et al, 1999; Zander et al, 1999; Byrne et al, 2000; Finke et al, 2000). In a recent randomised trial, we showed that rabbit anti thymocyte globulin (ATG) significantly reduced the risk of grade III–IV acute GvHD in unrelated donor transplants (Bacigalupo et al, 2001a). However, TRM and survival were unchanged due to a higher risk of lethal infections in the ATG 15 mg/kg arm (Bacigalupo et al, 2001a). An update of the same study showed that ATG provided significant protection against acute and chronic GvHD, shortened time to terminate immunosuppression and improved quality of life (Bacigalupo et al, 2006). Whether different schedules of administration of ATG or different agents may further improve results remains to be determined. Expanding regulatory T cells (TREGS) CD4+ CD25+ immunoregulatory T cells (TREGS) can be administered to inhibit GVHD while preserving graft- versus-leukaemia activity after allogeneic bone marrow transplantation in mice. Preclinical studies suggest that it is Review ª 2007 The Author 88 Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98
  3. 3. necessary to infuse as many TREGS as conventional donor T cells to achieve a clinical effect on GVHD (Trenado et al, 2006). How do we translate this to the clinic? The Stanford group has designed a transplant programme consisting of fractionated TLI (800 rads delivered in 2 weeks, 80 rads/ d ·5 ·2) and ATG (5 d) followed by allogenic unmanipulated peripheral blood transplants (Lowsky et al, 2005), resulting in little or no acute GvHD. A recent update of that study at the 2006 meeting of the European Group for Blood and Marrow Transplantation (EBMT) has confirmed these results of 64 patients, half of whom received grafts from unrelated donors (R. Lowski, unpublished observations). Post-transplant immunosuppressive therapy This therapy is still the conventional form of GvHD prevention both in HLA-identical as well as unrelated-donor transplants. It is usually based on the combination of cyclosporin A (CsA) and short course methotrexate (MTX) on days+1, +3, +6, +11 (Storb et al, 1986; Zikos et al, 1998). The CsA dose used in the first 10 d post-transplant may have a significant impact on leukaemia control: in two prospective randomised trials, both in children and in adults, low-dose CsA (1 mg/kg) was shown to protect patients from leukaemia relapse when compared with higher doses of CsA (3 mg/kg or 5 mg/kg) (Bacigalupo et al, 1991; Locatelli et al, 2000). This was recently confirmed at a 10-year follow up (Bacigalupo et al, 2001b) and should be kept in mind especially when grafting patients at high risk of relapse. Recently tacrolimus (FK506), a calcineurin inhibitor, has been introduced in the prophylaxis of GvHD: 180 patients grafted from a matched unrelated donor were randomised to receive CsA+MTX or FK506+MTX (Nash et al, 2000). Acute GvHD II-IV was significantly lower (51%) in FK506-treated patients when compared with the CsA patients (70%) (P ¼ 0Æ0002), but this did not translate in a lower risk of chronic GvHD. The adverse events, in particular nephrotox- icity, infections or leukaemia relapses were not significantly different (Nash et al, 2000). There was also no difference in survival. Therefore, both CsA+MTX and FK506+MTX com- binations offer some protection for GvHD and have signifi- cantly reduced the risk of severe GvHD when compared to single agent prophylaxis (MTX or CyA alone). Mycophenolate mofetil (MMF) has been successfully introduced for GvHD prevention, and may substitute MTX in the standard CsA combination, mainly because of less mucositis and overall good tolerance (Basara et al, 2000; Nash et al, 2005; Neumann et al, 2005). Mesenchymal stem cells Mesenchymal stem cell (MSC) are pluripotent stem cells capable of generating osteoblasts, myoblats, condroblasts, tenoblasts, adipocytes and stromal cells (Pittenger et al, 1999). There have been several reports on the immunosup- pressive effect of MSC, both in vitro (Klyushnenkova et al, 1998; Tse et al, 2000). and in vivo (Bartholomew et al, 2002). The co-infusion of a large number of osteoblasts together with hemopoietic stem cells, in a mismatched mouse model, resulted in successful engraftment and immune reconstitution (El-Badri et al, 1998), whereas control animals died of GvHD or rejection. A recent trial has been completed in 40 patients with haematological malignancies, using expanded MSC from an HLA-identical sibling, and co-infusing these cells with a conventional unmanipulated bone marrow (BM) or periph- eral bood (PB) transplant: the infusion of MSC was safe, and this was the primary end point of the study (El-Badri et al, 1998); in addition, hemopoietic reconstitution was prompt. However, the study failed to show a significant reduction in acute or chronic GvHD when these patients were compared with a matched pair cohort of CIBMTR patients (El-Badri et al, 1998). MSC are now being co-transplanted in different settings, such as cord blood or unrelated marrow grafts. One has to note that the number of MSC or osteoblasts given to animals (El-Badri et al, 1998) exceeds the numbers given to humans by at least 3 logs (Lazarus et al, 2005): if we want to achieve what has been shown in the experimental models, perhaps we will need to escalate the number of MSC we infuse. Inactivation of antigen presenting cells Depleting host APC before the conditioning regimen may reduce GvHD: in keeping with this observation, patients receiving extracorporeal photopheresis (ECP) before the conditioning regimen have a low incidence of GvHD (Chan et al, 2001), because ECP may downregulate host APC (Gorgun et al, 2001). It is also understood that broad specificity T cell antibodies (ATG and CAMPATH), commonly used in allotransplants, significantly deplete host APC cells. An other way of killing APC is by using natural killer (NK) cells. Ruggeri et al (2001) showed that elimination of host APC in the mouse, using donor incompatible NK cells, made the recipients resistant to GvHD (they could be infused with large numbers of mismatched T cells, without GvHD). Thus expanding donor NK cells may be one way of reducing GvHD, and some centres have started to investigate whether donor NK cells can be expanded and co-infused to reduce GvHD, and possibly also to kill tumour cells (Aversa et al, 1998). Indeed, in the best possible donor-recipient combination, donor NK cells would reduce GvHD (by killing host APC), reduce rejection (by killing host T cells) and reduce relapse (by killing leukaemia cells). Whether we will be able to use NK cells so cleverly remains to be determined, Reduced-intensity conditioning regimens Reduced-intensity conditioning (RIC) regimens were intro- duced in the late 1970s when busulfan 8 mg/kg was used instead of the conventional 16 mg/kg, in children with inborn errors (Hobbs et al, 1981). These regimens are usually associated with less severe (or delayed) acute GvHD, because Review ª 2007 The Author Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98 89
  4. 4. of the persistence of host cells (mixed chimaeras), which counteract GvHD (Mielcarek & Storb, 2005), although early GvHD may still occur (Mielcarek et al, 2005). There may also be a lower level of inflammatory cytokines. RIC regimens based on low-dose TBI (2 Gy) (Storb et al, 1999), low-dose busulfan (Slavin et al, 1998), low-dose thiotepa (Raiola et al, 2000) low-dose melphalan (Kottaridis et al, 2000) or cyclo- phosphamide and fludarabine (Khouri et al, 1998) are being used widely in elderly patients up to the age of 70 years, and the overall risk of GvHD is probably less than what would be seen in patients of the same age with conventional intensity regimens. Acute GvHD still remains a major obstacle after RIC HSCT, occurring in 15% of patients in its severe form (grade III–IV), while extensive chronic GvHD is diagnosed in 50% of all patients (Bacigalupo, 2002). Several questions need to be answered in this context: timing and intensity of in vivo immunosuppression, timing of CsA discontinuation, timing of DLI, and use of T-cell antibodies. Some regimens include anti- T cell antibodies, such as alentuzumab (CAMPATH) (Kottar- idis et al, 2000) or ATG (Slavin et al, 1998). It is interesting that Russell and coworkers have taken a different approach: they used ablative doses of intravenous busulfan combined with fludarabine and tried to maximise GvHD prevention with rabbit ATG in the conditioning regimen and CsA MTX for postgraft immunosuppression (Russell et al, 2002). The pro- gramme, designated FLU-BUP, was given up to the age of 65 years, for patients with haematological malignancies, and yields a TRM of 4% in HLA-identical siblings and 20% in unrelated transplants. Anti-IL2 anti-TNF antibodies Other monoclonal antibodies (mAbs) that interact with IL2 or TNF have been tested in the clinical setting. Anti- CD25 mAb seemed to delay the occurrence of GvHD; in a randomised trial the administration of a CD25 mAb (in addition to CsA+MTX) appeared to decrease leukaemia-free survival, in comparison to conventional GvHD prophylaxis (Blaise et al, 1995). A humanised CD25 mAb, assessed in a double-blind, placebo-controlled randomised study, involving a total of 210 patients, failed to prevent GvHD or improve the outcome of unrelated HSCT recipients (Anasetti et al, 1995). A mAb neutralising TNF-a has also been tested in 21 patients as GvHD prophylaxis: in a prospective trial Holler et al (2002) showed that GvHD could be delayed (by 10 d), although the overall grading was similar to controls. Can GvHD be prevented? The answer is clearly yes, and there has been a progressive decline in the severe form of acute GvHD (III–IV) in the last decade (Bacigalupo et al, 2004). Whether reduction of GvHD produces improved survival, is a more difficult question. However, this should not discourage further studies on GvHD prevention, because if survival is comparable, morbidity is clearly lower if patients do not experience acute or chronic GvHD. Can acute GvHD be treated? First-line treatment Corticosteroids Corticosteroids are used as first-line therapy: in a study of 443 patients who received prednisone 60 mg/m2 for 14 d as first-line therapy, followed by an 8-week taper, an overall improvement was observed in 55% of the patients with durable (‡28 days) complete responses in 35% (Blazar, 2002). The probability of survival at 1 year after initiation of therapy was 53%: favourable predictors of survival were younger patient age, HLA-identical sibling donor and GvHD prophylaxis other than ex-vivo T cell depletion (Blazar, 2002). The authors of this important study concluded that steroids provide an active but inadequate therapy for acute GvHD, especially in patients with severe GvHD, and that more effective prophylaxis for mismatched and unrelated donor transplants is needed. Unfortunately. There is no evidence that more aggressive first-line therapy is beneficial: the Italian Group for Marrow Transplantation (GITMO) could not show an advantage of high-dose steroids (10 mg/kg of 6-MPred) over conventional 2 mg/kg MPred, with a transplant mortality at 1 year of 30% in both groups (Van Lint et al, 1998). A randomised study comparing steroids + ATG versus steroids alone came to the same conclusion (Cragg et al, 2000). Two additional observations were made in the GITMO study: (i) despite the very early day of randomization (median day +12 from transplant), high dose MPred did not prevent progression towards grade III–IV GvHD and (ii) responders to 5 d of 6MPred 2 mg/kg had a significantly lower TRM (16%) when compared with non-responders (46%) (Van Lint et al, 1998). We have confirmed this result in a more recent study (Van Lint et al, 2006). Thus, primary treatment of acute GvHD should be pred- nisone or 6MPred 2 mg/kg/d for 5 d (Fig 1): responsive patients should taper steroid therapy. An IBMTR survey confirmed that a 5-d course is sufficient to identify steroid- refractory acute GvHD (Hsu et al, 2001). There may be less agreement on criteria to define response on day+5 or day+7: it is unlikely that patients will be free of GvHD. The most common situation will be reduction of clinical signs of acute GvHD, which may allow reduction of the 6MPred dose (Fig 1): indeed in two consecutive studies we found it very useful to identify day+5 responders as those patients who were considered eligible for MPred dose tapering (Cragg et al, 2000; Van Lint et al, 2006). The probability of response will be higher for patients who have limited acute GvHD on day 0 of treatment (Van Lint et al, 2006). Patients not responding on day+5 or day+7 could not reduce their dose of steroidsand were eligible for second-line treatment (Fig 1). Transplant mortality is higher (as expected) in non-responders as compared to day+5 responders, and this indicates that Review ª 2007 The Author 90 Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98
  5. 5. strategies for second-line therapy can be designed very early in the course of the disease. Second-line treatment A large number of studies have been performed for patients not responding to 2 mg/kg of MPred (Fig 1). Most of these were phase II uncontrolled studies, showing some degree of response with the use of a large variety of agents. Very few were prospective randomised trials, and these have failed to show any advantage of experimental treatment over standard steroid therapy. Anti-thymocyte globulin (ATG) Anti-thymocyte globulin is one treatment option for steroid-refractory patients, and some encouraging results have come from phase II trials (Roy et al, 1992; Aschan, 1994), especially when ATG was given early after the diagnosis of GvHD (MacMillan et al, 2002). However, we are lacking evidence that ATG improves survival. In a recent prospective randomised trial the Italian group GITMO has been unable to confirm that ATG is beneficial as a second-line therapy of steroid-refractory acute GvHD (Van Lint et al, 2006): 61 patients not responding to 5 d of MPred 2 mg/kg, were randomised to receive MPred 5 mg/kg/d for 10 d, alone (n ¼ 34) or in combination with rabbit ATG (n ¼ 27). The two groups were balanced for clinical and GvHD characteristic. One-month after randomisation 26% had a complete response, 25% a partial response, 33% stable GvHD, 10% worsened and 8% had died: there was no significant difference in response, TRM and survival between the non-ATG and ATG group (Van Lint et al, 2006). Five-year actuarial survival was 36% and 34% for controls and ATG patients. Therefore, although ATG can induce a significant response in GvHD patients, survival is unchanged when compared with patients not receiving ATG: clinical response of GvHD does not mean improved survival, and responders may still die of infections and other complications, as suggested in a recent review (Antin et al, 2004). Interleukin 2 receptor antibodies There are several monoclonal antibodies to IL2 (reviewed in Antin et al (2004): denileukin difitox (Ontac), inolinomab (Leukotac), Basiliximab (Simulect), Daclizumab (zenapax). They have all shown efficacy in steroid-resistant acute GvHD (Antin et al, 2004). Nevertheless, infections remain a serious problem: is this due to the fact that patients come to monoclonal antibody therapy after failing several lines of treatment? Perhaps early administration of IL2R antibodies would prove more effective. A large prospective randomised trial is ongoing within the National Marrow Donor Program, testing, among other agents, an IL2 receptor antibody. Anti -CD147 monoclonal antibody Deeg et al (2001) have reported a pilot study on the use of anti-CD147 (a neurothelin member of the immunoglobulin superfamily which is upregulated on activated T and B cells): 27 patients with GvHD entered this study and 51% were considered as responders, including 25% complete responses. Survival at 6 months was 44% (Deeg et al, 2001). TNF antibodies Tumour necrosis factor is of one the inflammatory cytokines mediating cellular cytotoxicity. TNF can be downregulated by steroids, pentoxifilline, transforming-growth factor beta (TGFB) and IL4. Antibodies to TNF (infliximab) or to the TNFreceptor (etanercept) have been developed and used both in first- and second-line treatment of acute GvHD (Marty et al, 2003; Couriel et al, 2004; Uberti et al, 2005). Responses are seen, some patients clear their symptoms rapidly, but infections remain an issue (Marty et al, 2003). Other agents Other agents, such as MMF are being tested with some success: MMF has a good efficacy profile, is well tolerated in general and may prove useful in sparing steroids and steroid-associ- ated complications (Antin et al, 2004). Pre-emptive treatment We have previously shown that patients at high risk of GvHD and TRM can be identified on day +7 following an allogeneic Methylprednisolone 2 mg/kg/d x5 or 7 d Response 1st line treatment Day 0 Day 7 2nd line treatment Taper MPred No response Diagnosis of Acute GvHD MPred 2–5 mg/kg ATG, anti-IL2, anti-CD147 TNF antibodies MMF, ECP Mesenchymal Stem Cells Other Fig 1. Flow chart of events after the diagnosis of acute GvHD is made (day 0). First-line treatment consists of methylprednisolone (Mpred) 2 mg/kg/d i.v. for 5 or 7 d. On day 7, responders are assigned to a steroid-taper programme. Non-responders receive second-line therapy: there are a number of options. Continue MPred alone; add antithymocyte globulin (ATG), monoclonal antibodies to interleukin 2 (IL2), tumour necrosis factor (TNF), CD147, add extracorporeal photopheresis (ECP). The most promising option today seems the addition of mesenchymal stem cells (MSC). Review ª 2007 The Author Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98 91
  6. 6. bone marrow transplant (BMT), based on serum bilirubin and blood urea nitrogen levels (Bacigalupo et al, 1999): we have recently revised the scoring system with the inclusion of day+7 cholinesterase, gammaglutamyltransferase, total protein to- gether with cell dose and donor type (Sormani et al, 2003). One possible approach to reduce the risk of GvHD and TRM, is pre-emptive treatment before the disease develops. In a pilot study, we tested the feasibility of this approach in patients undergoing an alternative donor HSCT: the risk of severe GvHD and the actuarial 1 year TRM was reduced in the ATG treated patients (Bacigalupo et al, 2001c). This is in keeping with a previous randomised trial, published some years ago, showing that early administration of ATG after an HLA- identical sibling transplant, could significantly reduce the risk of acute GvHD (Ramsay et al, 1982). Whether this will translate in survival advantage is being now tested in a prospective multicenter trial by GITMO. Cellular therapy of GvHD This section includes the use of MSC, ECP directed against APC, and suicide gene transduced T cells Suicide gene transduction of T cells This approach is based on transducing T cells with a gene, such as herpes simplex virus thymidine kinase (HSV-TK) which renders them susceptible to killing by ganciclovir, provided the cell is also dividing. The T cells are infused into the host and when GvHD develops, ganciclovir is given, killing only transduced T cells. This system requires efficient gene transduction and the ability to select transduced cells. It has been implemented in humans and animals models with some positive results, although anectotal (Bonini et al, 1997). The model is based on the hypothesis, that established GvHD can be turned off by killing alloreactive T cells, although there is scanty evidence that this can be achieved: the activation system is very complex, and by the time it is established there are many cell types (both of donor and recipient origin) and many cytokines involved, often with opposite actions. During induction phase the administration of IL12 inhibits GvHD (Sykes et al, 1995). If, in the same mouse model, IL12 was given later after transplant, there was enhancement of GvHD by induction of host-derived interferon-c (IFNc) (Sykes et al, 1999). T cells from IFNc knock-out mice, surprisingly, caused a more virulent GvHD, suggesting a protective effect of IFNc (Murphy et al, 1998). In a different mouse P¤ F1 model, the lack of IFNc T cells delayed GvHD (Minasi et al, 1993). These results outline the complex pathogenesis of GvHD and the multiple effectors involved, which may vary according to the animal model chosen. If this is the case, can GvHD be turned off by killing T cells, and if so, which T cells need to be killed? Although suicide gene transduction was reported almost 10 years ago, and despite some pilot phase I/II studies, it has not been used in the clinic as a standard approach for acute GvHD prevention and treatment: it faces numerous problems, including logistic, technical and conceptual. For the time being, it remains an interesting investigational tool. Mesenchymal stem cells There has been great interest in the use of MSC for treatment of acute GvHD in the past few years (Ringden et al, 2006): at the EBMT meeting 2006 we presented a cooperative report on patients treated in Huddinge, Genova and Pavia, and we further updated this report at the 2006 ASH meeting (Le Blanc et al, 2006): 40 patients with grades III–IV acute GvHD receiving MSC were evaluated. The median MSC dose was 1Æ0 (range 0Æ4–9) 106 cells/kg body weight of the recipient. No side-effects were seen after MSC infusions. Nineteen patients received one dose, 19 patients received two doses, two patients received three and five doses, respectively. MSC donors were HLA-identical siblings in five cases, haploidentical in 19 cases and third-party HLA-mismatched in 41 cases. Among the 40 patients treated for severe acute GvHD, 19 had complete responses, nine showed improvement, seven patients did not respond, four had stable disease and one patient was not evaluated due to short follow-up. Twenty-one patients were alive between 6,weeks up to 3Æ5 years after transplantation, Nine of whom had extensive chronic GvHD. These results suggest that immunomodulatory and tissue repairing effects of MSC should be further explored as treatment of severe acute GvHD in prospective randomised trials, especially as there have been negative reports in the experimental model (Sudres et al, 2006). Extracorporeal photopheresis Extracorporeal photopheresis has been mostly used in patients with chronic GvHD, and significant responses have been seen in a proportion of patients (Couriel et al, 2006). A randomised study has been completed in chronic GvHD patients, and should be available for definitive analysis this year (Greinix et al, 2006a). Recent reports have been published, of ECP used for acute GvHD: the procedure is invasive, requires a dedicated team at the Blood Bank and responses are not seen before 12 weeks, therefore requiring long-term supportive care (Gar- ban et al, 2005; Greinix et al, 2006b). However, given the current poor results with second-line therapy, waiting 12 weeks for a response would not be the greatest of problems. Greinix et al (2006b)) reported an 82% complete response rate for patients with severe skin acute GvHD treated with ECP and steroids, 61% for gut involvement and 61% for liver involve- ment. A randomised trial comparing prednisone + ECP versus prednisone alone has been activated this year. Can GvHD be treated ? The answer is a cautious ‘Yes’. Most events occur very early in the course of the transplant. First-line therapy with conven- tional dose steroids (1–2 mg/kg/d) can be successfully given to over half of affected patients. Response depends on the severity of GvHD and organ involvement. If patients respond, their Review ª 2007 The Author 92 Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98
  7. 7. transplant mortality is relatively low; if they don’t respond to first-line treatment, their transplant mortality is high (possibly exceeding 60%). Mortality after second-line therapy has not been reduced in the last three decades: patients do respond to second-line therapy and GvHD severity is diminished, but the patients may still succumb to infectious complications. New agents, antibodies or intensified immunosuppression have not changed GvHD-related mortality, cellular therapy holds promise. The important take-home message is: whatever you decide to do, please enter your patients in to a clinical trial (Bolanos-Meade & Vogelsang, 2005): this is the only way we can expect to make progress in the near future. Can we improve immune-reconstitution ? Immune reconstitution remains a significant problem follow- ing allogeneic stem cell transplantation and several studies have analysed this. The number of NK cells, as monitored by CD56 or CD16 expression on peripheral blood lymphocytes, rose rapidly after transplant, and returned quickly to the normal range while CD8+ cells frequently remained high (Dokhelar et al, 1981). There is a strong imbalance of helper/ suppressor cells, first described many years ago (Bacigalupo et al, 1981), which still needs to be fully understood. It may be associated with immune reconstitution or with alloreactivity (Noel et al, 1978; Paulin et al, 1987; Barrett et al, 2003): the former seems more probable, since the CD4/CD8 ratio is not a good indicator of acute GvHD. Other factors associated with poor immune recovery also predict GvHD: older age (Seddik et al, 1984), unrelated donors (Small et al, 1999) and of course steroid therapy given to treat GvHD (Douek et al, 2000). The thymus plays an important role in reconstitution of T-cell immunity and increasing patient age has an adverse effect on the regeneration of naive CD4+ T cells, probably due to age- related thymic involution: these observations were confirmed by TCR rearrangement excision circlet (TREC) assay to measure thymic output (Douek et al, 1998, 2000; ). Attempts to boost immune reconstitution by IL7 or IL7-engeneered cells have been reported (Li et al, 2006), but we have not yet seen these studies translated in the clinic. Recently, keratinocyte growth factor (KGF) has been shown to promote immune reconstitution after HSCT in the animal model (Min et al, 2002): trials using KGF are underway in clinical allograft programs. Immune reconstitution is inversely correlated with the severity of GvHD: the more severe the disease the worse the immune recovery (Sale et al, 1992). The situation is worsened by treatment of GvHD with steroids, antibodies and other suppressive manoeuvres. Attempts to manipulate immune recovery with cytokines have failed so far, although IL7 holds promise. Infections are a frequent and often lethal complica- tion: they include viral, fungal and bacterial infections in patients with GvHD. Discussing these complications is outside the scope of the present review, however, monitoring and early treatment of infections should be a major part of standard protocols or prospective trials. This is also relevant because of the many old and new agents available to treat cytomegalovirus (CMV), Epstein–Barr virus (EBV), aspergillus and vancomy- cin-resistant enterococci. We can not leave this section without mentioning the elegant studies, pursued by several groups, in expanding antigen-specific T cells (Peggs et al, 2001; Rauser et al, 2004; Perruccio et al, 2005; Bollard et al, 2006; Riddell et al, 2006): immunity to CMV, EBV and aspergillus has been successfully transferred with expanded antigen-specific T cells, with no GvHD, and with clearance of the infection. A very powerful proof-of-principle indeed. Thus the technology is now estab- lished, but is the cost and the laboratory resources affordable for most transplant centres? Possibly not, but developing this technology should advance our ability to manipulate the immune system, and this is important for the management of transplants, and possibly also for the treatment of tumours. Is acute GVHD influenced by stem cell source? What about the three stem cell sources: PB, BM, cord blood (CB). They are listed here in the order of current ‘preference’, because numbers do represent what happens every day in our centres. The last EBMT survey told us that allogeneic PB is the preferred source, followed by BM and CB. The influence on acute and chronic GvHD is probably also falls in the same order; PB, BM, CB. There are four large international randomised studies that used BM or PB as the source of stem cells (Blaise et al, 2000; Bensinger et al, 2001; Couban et al, 2002; Schmitz et al, 2002). Acute GvHD grade III–IV was similar in three studies, and significantly increased in PB recipients in one study (Schmitz et al, 2002). It is therefore reasonable to say that acute GvHD was rather comparable in patients receiving allogeneic BM or PB cells, although chronic GvHD was significantly increased in almost all studies. Three recent publications have set the stage for HLA-identical sibling CB transplants (Rocha et al, 2000) and for unrelated CB transplants in children (Rocha et al, 2001) and in adults (Laughlin et al, 2001). Common to these three publications is the low risk of acute and chronic GvHD for patients receiving CB transplants: in the HLA-identical study, the risk of acute GvHD was 0Æ41 for CB when compared with BM (P ¼ 0Æ001) and for chronic GvHD the risk was 0Æ35 (P ¼ 0Æ02). But, perhaps comparing unmanipulated PB, BM and CB is not the right question at present: efforts should be made to optimise programs involving each of these stem cell sources: we will then find patients who might benefit from the different impact these stem cell sources have on GvHD and outcome. Conclusions Treatment of established GvHD is complex and has not made major advances in the last decade. Possibly we treat our patients too late, when tissue damage has already taken place Review ª 2007 The Author Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98 93
  8. 8. and cytokine production by activated donor T cells and autologous macrophages can proceed undisturbed. It would seem that acute GvHD is, to a certain extent, self-programmed, since very early treatment with high dose corticosteroids and/ or ATG does not modify the natural course of the disease. Over the last three decades we have considerably reduced the risk of acute GvHD and understood how to prevent it by modifying the transplant program and the stem cell source: we now need to improve our ability to predict GvHD and develop new strategies of early treatment. References Anasetti, C., Lin, A., Nademanee, A., Gluckman, E., Messner, H., Beatty, P., Chauncey, T., Jacobsen, N., Chao, N., Powles, R., Territo, M., Walker, I., Davis, J. & Light, S. (1995) A phase II/III randomized double blind, placebo-controlled multicentre trial of humanised anti-Tac for prevention of acute graft-versus-host disease in recip- ients of marrow transplantats from unrelated donors. Blood, 86(Suppl. 1), 621a. Antin, J.H., Chen, A.R., Couriel, D.R., Ho, V.T., Nash, R.A. & Weis- dorf, D. (2004) Novel approaches to the therapy of steroid resistant acute graft versus host disease. Biology of Blood and Marrow Transplantation, 10, 655–668. Aschan, J. (1994) Treatment of moderate to severe acute GvHD: a retrospective analysis. Bone Marrow Transplantation, 14, 601– 607. Aversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falz- etti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., Reisner, Y. & Martelli, M.F. (1998) Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. New England Journal of Medicine, 339, 1186–1193. Bacigalupo, A. (2002) Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplantation, 29, 191–195. Bacigalupo, A., Mingari, M.C., Moretta, L., Podesta`, M., Van Lint, M.T., Piaggio, G., Raffo, M.R. & Marmont, A. (1981) Imbalance of T-cell subpopulations and defective pokeweed mitogen-induced B- cell differentiation after bone marrow transplantation in man. Clinical Immunology and Immunopathology, 20, 137–145. Bacigalupo, A., van Lint, M.T., Occhini, D., Gualandi, F., Lamperelli, T., Sogno, G., Tedone, E., Frassoni, F., Tong, J. & Marmont, A.M. (1991) Increased risk of leukemia relapse with high-dose cyclos- porine A after allogeneic marrow transplantation for acute leukemia. Blood, 77, 1423–1428. Bacigalupo, A., Oneto, R., Bruno, B., Soracco, M., Lamparelli, T., Gualandi, F., Occhini, D., Raiola, A.M., Mordini, N., Berisso, G., Bregante, S., Dini, G., Lombardi, A., Van Lint, M.T. & Brand, R. (1999) Early predictors of transplant-related mortality (TRM) after allogeneic bone marrow transplants (BMT): blood urea nitrogen (BUN) and bilirubin. Bone Marrow Transplantation, 24, 653–659 Bacigalupo, A., Lamparelli, T., Bruzzi, P., Guidi, S., Alessandrino, P.E., di Bartolomeo, P., Oneto, R., Bruno, B., Barbanti, M., Sacchi, N., van Lint, M.T. & Bosi, A. (2001a) Antithymocyte globulin for graft- versus-host disease prophylaxis in transplants from unrelated do- nors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood, 98, 2942–2947. Bacigalupo, A., Lamparelli, T., Gualandi, F., Bregante, S., Raiola, A.M., Di Grazia, C., Dominietto, A., Romagnani, C., Occhini, D., Frassoni, F. & van Lint, M.T. (2001b) Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia: a 10 year follow up of a randomized study. Blood, 98, 3174–3175. Bacigalupo, A., Oneto, R., Lamparelli, T., Gualandi, F., Bregante, S., Raiola, A.M., Di Grazia, C., Dominietto, A., Romagnani, C., Bruno, B., Van Lint, M.T. & Frassoni, F. (2001c) Pre-emptive therapy of acute graft versus host disease: a pilot study with anti-thymocyte globulin (ATG). Bone Marrow Transplantation, 28, 1093–1096. Bacigalupo, A., Soriani, M.P., Lamparelli, T., Gualandi, F., Occhini, D., Bregante, S., Raiola, A.M., di Grazia, C., Dominietto, A., Tedone, E., Piaggio, G., Podesta, M., Bruno, B., Oneto, R., Lombardi, A., Frassoni, F., Rolla, D., Rollandi, G., Viscoli, C., Ferro, C., Garbar- ono, L. & Van Lint, M.T. (2004) Reducing transplant-related mor- tality after allogeneic hematopoietic stem cell transplantation. Haematologica, 89, 1238–1247. Bacigalupo, A., Lamparelli, T., Barisione, G., Bruzzi, P., Guidi, S., Alessandrino, P.E., di Bartolomeo, P., Oneto, R., Bruno, B., Sacchi, N., van Lint, M.T., Bosi, A. Gruppo Italiano Trapianti Midollo Osseo (GITMO). (2006) Thymoglobulin prevents chronic graft- versus-host disease, chronic lung dysfunction, and late transplant- related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biology of Blood and Marrow Transplantation, 12, 560–565. Barrett, A.J., Rezvani, K., Solomon, S., Dickinson, A.M., Wang, X.N., Stark, G., Cullup, H., Jarvis, M., Middleton, P.G. & Chao, N. (2003) New developments in allotransplants immunology. Hematology American Society of Hematology. Education Program, 102, 350– 371.Review. Bartholomew, A., Sturgeon, C., Siatskas, M., Ferrer, K., McIntoch, K., Patil, S., Hardy, W., Devine, S., Ucker, D., Deans, R., Mosely, A.M., Hoffman, R. & Nchleunng, M. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Experimental Hematology, 30, 42–48. Basara, N., Blau, W.I., Kiehl, M.G., Schmetzer, B., Bischoff, M., Kirsten, D., Gunzelmann, S. & Fauser, A.A. (2000) Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clinical Transplantation, 14, 121– 126. Baurmann, H., Bonnefoy-Be´rard, N., Thiede, C. Oelschlagel, U., Eh- ninger, G., Revillard, J.P. & Schwerdtfeger, R. (1999) Clinical and biological effects of ATG used as part of the conditioning in matched unrelated donor (MUD) transplantation. Blood, 94, 134a. Bensinger, W.I., Martin, P.J., Storer, B., Clift, R., Forman, S.J., Negrin, R., Kashyap, A., Flowers, M.E., Lilleby, K., Chancey, T.R., Storb, R. & Appelbaum, F.R. (2001) Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. New England Journal of Medicine, 344, 175–181. Blaise, D., Olive, D., Michallet, M., Marit, G., Leblond, V. & Mar- aninchi, D. (1995) Impairment of leukaemia-free survival by addi- tion of interleukin-2- receptor antibody to standard graft-versus- host prophylaxis. Lancet, 345, 1144–1146 Blaise, D., Kuentz, M. & Container, C. (2000) Randomized trial of bone marrow versus lenograstim primed blood cell allogeneic transplantation. Journal of Clinical Oncology, 18, 537–546. Review ª 2007 The Author 94 Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98
  9. 9. Blazar, B.R. (2002) Response of 443 patients to steroids as primary therapy for acute GvHD: comparison of grading systems. Biology of Blood and Marrow Transplantation, 8, 387–394. Bolanos-Meade, J. & Vogelsang, G.B. (2005) Novel strategies for steroid-refractory acute graft-versus-host disease. Current Opinion in Hematology, 12, 40–44.Review. Bollard, C.M., Gottschalk, S., Huls, M.H., Molldrem, J., Przepiorka, D., Rooney, C.M. & Heslop, H.E. (2006) In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantation. Leukemia & Lymphoma, 47, 837–842. Bonini, C., Ferrari, G., Verzeletti, S., Servida, P., Zappone, E., Ruggieri, L., Ponzoni, M., Rossini, S., Mavilio, F., Traversari, C. & Bordignon, C. (1997) HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia. Science, 276, 1719–1724. Byrne, J.L., Stainer, C., Cull, G., Haynes, A.P., Bessell, E.M., Hale, G. & Waldmann, H. (2000) The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplanta- tion for leukaemia. Bone Marrow Transplantation, 25, 411–417. Chan, G., Foss, F.M., Roberts, T., Sprague, K., Schenkein, D. & Miller, K.B. (2001) Decreased acute and chronic graft versus host disease with early full donor engraftment following a pentostatin-based preparative regimen for allogeneic bone marrow transplant in high- risk patients. Blood, 98, 383a, (abstr. 1612). Couban, S., Simpson, R., Barnett, M.J. & Bredeson, C. (2002) A ran- domized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood, 100, 1525–1528. Couriel, D., Saliba, R., Hicks, K., Ippoliti, C., de Lima, M., Hosing, C., Khouri, I., Andersson, B., Gajewski, J., Donato, M., Anderlini, P., Kontoyiannis, D.P., Cohen, A., Martin, T., Giralt, S. & Champlin, R. (2004) Tumor necrosis factor alpha blockade for the treatment of acute GVHD. Blood, 104, 649–654. Couriel, D.R., Hosing, C., Saliba, R., Shpall, E.J., Anderlini, P., Rhodes, B., Smith, V., Khouri, I., Giralt, S., de Lima, M., Hsu, Y., Ghosh, S., Neumann, J., Andersson, B., Qazilbash, M., Hymes, S., Kim, S., Champlin, R. & Donato, M. (2006) Extracorporeal photo- chemotherapy for the treatment of steroid-resistant chronic GVHD. Blood, 107, 3074–3080. Cragg, L., Blazar, B.R., Defor, T., Kolatker, N., Miller, W., Kersey, J., Ramsay, M., McGlave, P., Filipovich, A. & Weisdorf, D. (2000) A randomized trial comparing prednisone with antithymocyte globu- lin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 6, 441–447 Deeg, H.J., Blazar, B.R., Bolwell, B.J., Long, G.D., Schuening, F., Cunningham, J., Rifkin, R.M., Abhyankar, S., Briggs, A.D., Burt, R., Lipani, J., Roskos, L.K., White, J.M., Havrilla, N., Schwab, G. & Heslop, H.E. (2001) Treatment of steroid-refractory acute graft- versus-host disease with anti-CD147 monoclonal antibody ABX- CBL. Blood, 98, 2052–2058. Dokhelar, M.C., Wiels, J., Lipinski, M., Tetaud, C., Devergie, A., Gluckman, E. & Tursz, T. (1981) Natural killer cell activity in hu- man bone marrow recipients. Early reappearance of peripheral blood natural killer activity in graft versus host disease. Transplan- tation, 31, 61–65. Dominietto, A., Raiola, A.M., van Lint, M.T., Lamparelli, T., Gualandi, F., Berisso, G., Bregante, S., Frassoni, F., Casarino, L., Verdini, S. & Bacigalupo, A. (2001) Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. British Journal of Haematology, 112, 219–227. Douek, D.C., McFarland, R.D., Keiser, P.H., Gage, E.A., Massey, J.M., Haynes, B.F., Polis, M.A., Haase, A.T., Feinberg, M.B., Sullivan, J.L., Jamieson, B.D., Zack, J.A., Picker, L.J. & Koup, R.A. (1998) Change in thymic function with age and during the treatment of HIV in- fection. Nature, 396, 690–695. Douek, D.C., Vescio, R.A., Betts, M.R., Brenchley, J.M., Hill, B.J., Zhang, L., Berenson, J.R., Collins, R.H. & Koup, R.A. (2000) As- sessment of thymic output in adults after haematopoietic stem-cell transplantation and prediction of T-cell reconstitution. Lancet, 355, 1875–1881. El-Badri, N.S., Wang, B.Y. & Good, R.A. (1998) Osteoblast promote engraftment of allogeneic hematopoietic stem cells. Experimental Hematology, 26, 110–114. Ferrara, J.L. (2002) Cellular and cytokine effectors of acute graft versus host disease. International Journal of Hematology, 76(Suppl. 1), 195–198. Finke, J., Bertz, H., Schmoor, C., Veelken, H., Behringer, D., Wasch, R., Kunzmann, R., Heidecker, L., Lang, H., Meyer-Konig, U. & Mer- telsmann, R. (2000) Allogeneic bone marrow transplantation from unrelated donors using in vivo anti-T-cell globulin. British Journal of Haematology, 111, 303–313. Garban, F., Drillat, P., Makowski, C., Jacob, M.C., Richard, M.J., Favrot, M., Sotto, J.J., Bensa, J.C. & Cahn, J.Y. (2005) Extracorporeal chemophototherapy for the treatment of graft-versus-host disease: hematologic consequences of short-term, intensive courses. Hae- matologica, 90, 1096–1101. Glucksberg, H., Storb, R., Fefer, A., Buckner, C.D., Neiman, P.E., Clift, R.A., Lerner, K.G. & Thomas, E.D. (1974) Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation, 18, 295–304. Gorgun, G., Alcindor, T., Rao, R. & Foss, F. (2001) Immunologic mechanism of extracorporeal photochemotherapy (ECP) in chronic GVHD. Blood, 98, 650a, (abstr. 2729). Gratwohl, A., Brand, R., Apperley, J., van Biezen, A., Bandini, G., Devergie, A., Schattenberg, A., Frassoni, F., Guglielmi, C., Iacobelli, S., Michallet, M., Kolb, H.J., Ruutu, T. & Niederwieser, D. (2002) Graft- versus-host disease and outcome in HLA-identical sibling trans- plantations for chronic myeloid leukemia. Blood, 100, 3877–3886. Greinix, H.T., Socie, G., Bacigalupo, A., Holler, E., Edinger, M.G., Apperley, J.F., Schwarz, T., Ullrich, S.E., Albert, M.L., Knobler, R.M., Peritt, D. & Ferrara, J.L. (2006a) Assessing the potential role of photopheresis in hematopoietic stem cell transplant. Bone Marrow Transplantation, 38, 265–273. Greinix, H.T., Knobler, R.M., Worel, N., Schneider, B., Schneeberger, A., Hoecker, P., Mitterbauer, M., Rabitsch, W., Schulenburg, A. & Kalhs, P. (2006b) The effect of intensified extracorporeal photo- chemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica, 91, 405–408. Hansen, J.A., Gooley, T.A., Martin, P.J., Appelbaum, F., Chauncey, T.R., Clift, R.A., Petersdorf, E.W., Radich, J., Sanders, J.E., Storb, R.F., Sullivan, K.M. & Anasetti, C. (1998) Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. New England Journal of Medicine, 338, 962–968. Hobbs, J.R., Barrett, A.J., Chambers, D., James, D.C.O., Hugh-Jones, K., Byrom, N., Henry, K. & Lucas, C.F. (1981) Reversal of clinical Review ª 2007 The Author Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98 95
  10. 10. features of hurler’s disease and biochemical improvement after treatment by bone marrow transplantation. Lancet, 3, 709–712. Holler, E., Ledderose, G., Knabe, H., Muth, A., Gunther, C., Wilmanns, W. & Kolb, H.J. (1998) ATG serotherapy during pre-transplant conditioning in unrelated donor BMT: dose-dependent modulation of GVHD. Bone Marrow Transplantation, 21, 105a. Holler, E., Kolb, H.J., Mittermuller, J., Kaul, M., Ledderose, G., Duell, Th., Seeber, B., Schleuning, M., Hintermeier-Knabe, R., Ertl, B., Kempeni, J. & Wilmanns, W. (2002) Modulation of acute graft- versus-host disease after allogeneic bone marrow transplantation by tumor necrosis factor a (TNF a) release in the course of pretrans- plant conditioning: role of conditioning regimens and prophylactic application of a monoclonal antibody neutralizing human TNF a (MAK 195F). Biology of Blood and Marrow Transplantation, 8, 1–8. Hows, J., Bradley, B., Gore, S. Downie, T., Howard, M. & Gluckman, E. (1993) Prospective evaluation of unrelated donor bone marrow transplantation. Bone Marrow Transplantation, 12, 371–380. Hsu, B., May, R., Carrum, G., Krance, R. & Przepiorka, D. (2001) The criteria for steroid-refractory acute graft-versus host disease: an international practice survey. Blood, 98, 663a, (abstr. 2779). Jacobsohn, D.A. & Vogelsang, G.B. Anti-cytokine therapy for the treatment of graft-versus-host disease. Current Pharmaceutical Design, 10, 1195–1205. Khouri, I.F., Keating, M., Korbling, M., Przepiorka, D., Anderlini, P., Obrien, S., Giralt, S., Ippoliti, C., von Wolff, B., Gajewski, J., Do- nato, M., Claxton, D., Ueno, N., Andersson, B., Gee, A. & Champlin, R. (1998) Transplant lite: induction of graft versus malignancy using fludarabine based non ablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malig- nances. Journal of Clinical Oncology, 16, 2817–2824. Klyushnenkova, E.N., Mosca, J. & McIntosh, K.R. (1998) Human mesenchymal stem cells suppress allogeneic T cell responses in vitro: implications for allogeneic transplantation. Blood, 92, 642a. Kottaridis, P.D., Chakraverty, R., Milligan, D.W., Chakrabarti, S., Robinson, S., Chopra, R., Pettengell, R., Marsh, J., Mahendra, P., Schey, S., Morgan, G., Williams, C., Hale, G., Waldmann, H., Linch, D.C., Devereux, S., Glodstone, A.H. & Mackinnon, S. (2000) A non- myeloablative regimen for allogeneic stem cell transplantation with a low incidence of GVHD. Bone Marrow Transplantation, 25, S26. Lan, F., Zeng, D., Higuchi, M., Huie, P., Higgins, J.P. & Strober, S. (2001) Predominance of NK1.1+TCR alpha beta+ or DX5+TCR alpha beta+ T cells in mice conditioned with fractionated lymphoid irradiation protects against graft-versus-host disease: ‘‘natural sup- pressor’’ cells. Journal of Immunology, 167, 2087–2096. Laughlin, M.J., Barker, J., Bambach, B., Koc, O.N., Rizzieri, D.A., Wagner, J.E., Gerson, S.L., Lazarus, H.M., Cairo, M., Stevens, C.E., Rubinstein, P. & Kurtzberg, J. (2001) Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from un- related donors. New England Journal of Medicine, 344, 1860–1861. Lazarus, H.M., Koc, O.N., Devine, S.M., Curtin, P., Maziarz, R.T., Holland, H.K., Shpall, E.J., McCarthy, P., Atkinson, K., Cooper, B.W., Gerson, S.L., Laughlin, M.J., Loberiza, Jr, F.R., Moseley, A.B. & Bacigalupo, A. (2005) Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biology of Blood and Marrow Transplantation, 11, 389–398. Le Blanc, K., Frassoni, F., Ball, L., Lanino, E., Sundberg, B., Lonnies, L., Roelofs, H., Dini, G., Bacigalupo, A., Locatelli, F., Fibbe, W.F. & Ringden, O. (2006) Mesenchymal stem cells for treatment of severe acute graft-versus-host disease. Blood (ASH Annual Meeting Ab- stract), 108, 5304a. Lee, K.H., Choi, S.J., Lee, J.H., Lee, J.S., Kim, W.K., Lee, K.B., Sohn, S.K., Kim, J.G., Kim, D.H., Seol, M., Lee, Y.S., Lee, J.H. (2005) Prognostic factors identifiable at the time of onset of acute graft- versus-host disease after allogeneic hematopoietic cell transplanta- tion. Haematologica, 90, 939–948. Li, A., Zhang, Q., Jiang, J., Yuan, G., Feng, Y., Hao, J., Li, C., Gao, X., Wang, G. & Xie, S. (2006) Co-transplantation of bone marrow stromal cells transduced with IL-7 gene enhances immune recon- stitution after allogeneic bone marrow transplantation in mice. Gene Therapy, 13, 1178–1187. Locatelli, F., Zecca, M., Rondelli, R., Bonetti, F., Dini, G., Prete, A., Messina, C., Uderzo, C., Ripaldi, M., Porta, F., Giorgiani, G., Gir- aldi, E. & Pession, A. (2000) Graft versus host disease prophylaxis with low dose cyclosporine reduces the risk of relapse in children with acute leukemia given HLA identical sibling bone marrow transplantation: results of a randomized trial. Blood, 95, 1572–1579. Lowsky, R., Takahashi, T., Liu, Y.P., Dejbakhsh-Jones, S., Grumet, F.C., Shizuru, J.A., Laport, G.G., Stockerl-Goldstein, K.E., Johnston, L.J., Hoppe, R.T., Bloch, D.A., Blume, K.G., Negrin, R.S. & Strober, S. (2005) Protective conditioning for acute graft-versus-host disease. New England Journal of Medicine, 353, 1321–1331. MacMillan, M.L., Weisdorf, D.J., Davies, S.M., De For, T.E., Burns, L.J., Ramsay, N.K.C., Wagner, J.E. & Blazar, B.L. (2002) Early an- tithymocyte globulin therapy improves survival in patients with steroid-resistant acute graft-versus-host disease. Biology of Blood Marrow Transplantation, 8, 40–46. Maeda, Y., Reddy, P., Lowler, K.P., Liu, C., Bishop, D.K. & Ferrara, J.L. (2005) Critical role of host gammadelta T cells in experimental acute graft-versus-host disease. Blood, 106, 749–755. Marmont, A.M., Horowitz, M.M., Gale, R.P., Sobocinski, K., Ash, R.C., van Bekkum, D.W., Champlin, R.E., Dicke, K.A., Goldman, J.M. & Good, R.A. (1991) T-cell depletion of HLA-identical transplants in leukemia. Blood, 78, 2120–2130. Martin, P.J. & Kernan, N.A. (1997) T-cell depletion for GHD pre- vention in humans. In: Graft-versus-host disease (ed. by J.L.M. Fer- rara & H.J. Deeg), pp. 615–637. Marcel Dekker: New york. Marty, F.M., Lee, S.J., Fahey, M.M., Alyea, E.P., Soiffer, R.J., Antin, J.H. & Baden, L.R. (2003) Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non- Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients. A cohort study. Blood, 102, 2768–2776. Mc Donald, K.P., Rowe, V., Clouston, A.D., Welply, J.K., Kuns, R.D., Ferrara, J.L., Thomas, R. & Hill, G.R. (2005) Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. Journal of Immunology, 174, 1841–1850. Mielcarek, M. & Storb, R. (2005) Graft-vs-host disease after non- myeloablative hematopoietic cell transplantation. Leukemia & Lymphoma, 46, 1251–1260. Mielcarek, M., Burroughs, L., Leisenring, W., Diaconescu, R., Martin, P.J., Sandmaier, B.M., Maloney, D.G., Maris, M.B., Chauncey, T.R., Shizuru, J.A., Blume, K.G., Hegenbart, U., Niederwieser, D., For- man, S., Bruno, B., Woolfrey, A. & Storb, R. (2005) Prognostic relevance of ‘early-onset’ graft-versus-host disease following non- myeloablative haematopoietic cell transplantation. British Journal of Haematology, 129, 381–391. Review ª 2007 The Author 96 Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98
  11. 11. Min, D., Taylor, P.A., Panoskaltsis-Mortari, A., Chung, B., Danilenko, D.M., Farrell, C., Lacey, D.L., Blazar, B.R. & Weinberg, K.I. (2002) Protection from thymic epithelial cell injury by keratinocyte growth factor: a new approach to improve thymic and peripheral T-cell re- constitutionafterbonemarrowtransplantation.Blood,99,4592–4600. Minasi, L.E., Kamogawa, Y., Carding, S., Bottomly, K. & Flavell, R.A. (1993) The selective ablation of interleukin 2 producing cells iso- lated from transgenic mice. Journal of Experimental Medicine, 177, 1451–1459. Murphy, W.J., Welniak, L.A., Taub, D.D., Wiltrout, R.H., Taylor, P.A., Vallera, D.A., Kopf, M., Young, H., Longo, D.L. & Blazar, B.R. (1998) Differential effects of the absence of interferon-c and IL-4 in acute graft-versus-host disease after allogeneic bone marrow trans- plantation in mice. Journal of Clinical Investigation, 102, 1742–1748. Nash, R.A., Antin, J.H., Karanes, C., Fay, J.W., Avalos, B.R., Yeager, A.M. Przepiorka, D., Davies, S., Petersen, F.B., Bartels, P., Buell, D., Fitzsimmons, W., Anasetti, C., Storb, R. & Ratanatharathorn, V. (2000) Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus- host disease after marrow transplantation from unrelated donors. Blood, 96, 2062–2068. Nash, R.A., Johnston, L., Parker, P., McCune, J.S., Storer, B., Slattery, J.T., Furlong, T., Anasetti, C., Appelbaum, F.R., Lloid, M.E., Deeg, H.J., Kiem, H.P., Martin, P.J., Schubert, M.M., Witherspoon, R.P., Forman, S.J., Blume, K.G. & Storb, R. (2005) A phase I/II study of mycophenolate mofetil in combination with cyclosporine for pro- phylaxis of acute graft-versus-host disease after myeloablative con- ditioning and allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation, 11, 495–505. Neumann, F., Graef, T., Tapprich, C., Vaupel, M., Steidl, U., Germing, U., Fenk, R., Hinke, A., Haas, R. & Kobbe, G. (2005) Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplantation, 35, 1089–1093. Noel, D.R., Witherspoon, R.B., Storb, R., Atkinson, K., Doney, K., Mickelson, E.M., Ochs, H.D., Warren, R.P., Weiden, P.L. & Thomas, E.D. (1978) Does graft versus host disease influence the tempo of immunologic recovery after allogeneic human marrow transplan- tation? An observation on long-term survivors. Blood, 51, 1087– 1105. Ordemann, R., Hutchinson, R., Friedman, J., Burakoff, S.J., Reddy, P., Duffner, U., Braun, T.M., Liu, C., Teshima, T. & Ferrara, J.L. (2002) Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensifies acute graft-versus-host disease. Journal of Clin- ical Investigation, 109, 1249–1256. Paulin, T., Ringden, O. & Nilsson, B. (1987) Immunological recovery after bone marrow transplantation: role of age, graft versus host disease, prednisolone treatment and infections. Bone Marrow Transplantation, 1, 317–328. Peggs, K., Verfuerth, S. & Mackinnon, S. (2001) Induction of cyto- megalovirus (CMV)-specific T-cell responses using dendritic cells pulsed with CMV antigen: a novel culture system free of live CMV virions. Blood, 97, 994–1000. Perruccio, K., Tosti, A., Burchielli, E., Topini, F., Ruggeri, L., Carotti, A., Capanni, M., Urbani, E., Mancusi, A., Aversa, F., Martelli, M.F., Romani, L. & Velardi, A. (2005) Transferring functional immune responses to pathogens after haploidentical hematopoietic trans- plantation. Blood, 106, 4397–4406. Pittenger, M.F., MacKay, A.M. & Beck, C. (1999) Multilineage potential of adult human mesenchymal stem cells. Science, 284, 143–145. Raiola, A.M., van Lint, M.T., Lamparelli, T., Gualandi, F., Mordini, N., Berisso, G., Bregante, S., Frassoni, F., Sessarego, M., Fugazza, G., Di Stefano, F., Pitto, A. & Bacigalupo, A. (2000) Reduced intensity thiothepa-cyclophosphamide conditioning for allogeneic hemo- poietic stem cell transplants (HSCT) in patients up to 60 years of age. British Journal of Haematology, 109, 716–721. Ramsay, N.K.C., Kersey, J.H., Robinson, L.L., McGlave, P.B., Woods, W.G., Krivit, W., Kim, T.H., Goldman, A.I. & Nesbit, Jr, M.E. (1982) A randomized study of the prevention of acute graft versus host disease. New England Journal of Medicine, 306, 392–397. Rauser, G., Einsele, H., Sinzger, C., Wernet, D., Kuntz, G., Assenma- cher, M., Campbell, J.D. & Topp, M.S. (2004) Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood, 103, 3565–3572. Riddell, S.R., Bleakley, M., Nishida, T., Berger, C. & Warren, E.H. (2006) Adoptive transfer of allogeneic antigen-specific T cells. Biology of Blood and Marrow Transplantation, 12, 9–12. Ringden, O., Uzunel, M., Rasmusson, I., Remberger, M., Sundberg, B., Lonnies, H., Marschall, H.U., Dlugosz, A., Szakos, A., Hassan, Z., Omazic, B., Aschan, J., Barkholt, L. & Le Blanc, K. (2006) Me- senchymal stem cells for treatment of therapy-resistant graft-versus- host disease. Transplantation, 81, 1390–1397. Rocha, V., Wagner, Jr, J.E., Sobocinski, K.A., Klein, J.P., Zhang, M.J., Horowitz, M.M. & Gluckman, E. (2000) Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. New England Journal of Medicine, 342, 1846–1854. Rocha, V., Cornish, J., Sievers, E.L., Filipovich, A., Locatelli, F., Peters, C., Remberger, M., Michel, G., Arcese, W., Dallorso, S., Tiedemann, K., Busca, A., Chan, K.W., Kato, S., Ortega, J., Vowels, M., Zander, A., Souillet, G., Oakill, A., Woolfrey, A., Pay, A.L., Green, A., Gar- nier, F., Ionescu, I., Wernet, P., Sirchia, G., Rubinstein, P., Chevret, S. & Gluckman, E. (2001) Comparison of outcomes of unrelated bone marrow and umbelical cord blood transplants in children with acute leukemia. Blood, 97, 2962–2971. Rowlings, P.A., Przepiorka, D., Klein, J.P., Gale, R.P., Passweg, J.R., Henslee-Downey, P.J., Cahn, J.Y., Calderwood, S., Gratwohl, A., Socie, G., Abecasis, M.M., Sobocinski, K.A., Zhang, M.J. & Hor- owitz, M.M. (1997) IBMTR Severity Index for grading acute graft- versus-host disease: retrospective comparison with Glucksberg grade. British Journal of Haematology, 97, 855–864. Roy, J., McGlave, P.B., Filipovich, A.H., Miller, W.J., Blazar, B.R., Ramsay, N.K., Kersey, J.H. & Weisdorf, D.J. (1992) Acute graft versus-host disease following unrelated donor marrow transplanta- tion: failure of conventional therapy. Bone Marrow Transplantation, 10, 77–82. Ruggeri, L., Shlomchik, W.D., Capanni, M., Perruccio, K. & Velardi, A. (2001) Donor-vs-recipient alloreactive NK cells prevent gVHD by killing host APC in MHC disparate hematopoietic transplants. Blood, 98, 813a (abstr. 3378). Russell, J.A., Tran, H.T., Quinlan, D., Chaudhry, A., Duggan, P., Brown, C., Stewart, D., Ruether, J.D., Morris, D., Glick, S., Gyonyor, E. & Andersson, B.S. (2002) Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell trans- Review ª 2007 The Author Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98 97
  12. 12. plantation: study of pharmacokinetics and early clinical outcomes. Biology of Blood and Marrow Transplantation, 8, 468–476. Sale, G.E., Alavaikko, M., Schaefers, K.M. & Mahan, C.T. (1992) Ab- normal CD4:CD8 ratios and delayed germinal center reconstitution in lymphnodes of human graft recipients with graft-versus-host disease (GVHD): an immunohistological study. Experimental He- matology, 20, 1017–1021. Schmitz, N., Beksac, M., Hasenclever, D., Bacigalupo, A., Ruutu, T., Nagler, A., Gluckman, E., Russell, N., Apperley, J.F., Gorin, N.C., Szer, J., Bradstock, K., Buzyn, A., Clark, P., Borkett, K., Gratwohl, A., for the European Group for Blood and Marrow Transplantation. (2002) Transplantation of mobilized peripheral blood cells to HLA identical siblings with standard risk leukaemia. Blood, 100, 761–767. Seddik, M., Seemayer, T.A. & Lapp, W.S. (1984) The graft versus host reaction and immune function. T helper cell immunodeficiency associated with graft versus host induced thymic epithelial cell da- mage. Transplantation, 37, 281–286. Shlomchik, W.D., Couzens, M.S., Tang, C.B., McNiff, J., Robert, M.E., Liu, J., Shlomchik, M.J. & Emerson, S.G. (1999) Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science, 285, 412–415. Slavin, S., Nagler, A., Naparstek, E., Kapelushnik, Y., Aker, M., Civi- dalli, G., Varadi, G., Kirschbaum, M., Ackerstein, A., Samuel, S., Amar, A., Brautbar, C., Ben-Tal, O., Eldor, A. & Or, R. (1998) Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91, 756–763. Small, T.N., Papadopoulos, E.B., Boulad, F., Black, P., Castro-Mala- spina, H., Childs, B.H., Collins, N., Gillio, A., George, D., Jaku- bowski, A., Heller, G., Fazzari, M., Kernan, N., MacKinnon, S., Szabolcs, P., Young, J.W. & O’Reilly, R.J. (1999) Comparison of immune reconstitution after unrelated and related T-cell depleted bone marrow transplantation: effect of patient age and donor leu- kocyte infusions. Blood, 93, 467–480. Sormani, M.P., Oneto, R., Bruno, B., Fiorone, M., Lamparelli, T., Gualandi, F., Raiola, A.M., Dominietto, A., van Lint, M.T., Frassoni, F., Bruzzi, P. & Bacigalupo, A. (2003) A revised day +7 predictive score for transplant-related mortalita`: serum cholinesterase, total protein, blood urea nitrogen, c glutamil transeferase, donor type and cell dose. Bone Marrow Transplantation, 32, 205–211. Storb, R., Deeg, H.J., Whitehead, J., Appelbaum, F., Beatty, P., Ben- singer, W., Buckner, C.D., Clift, R., Doney, K., Farewell, V., Hansen, J., Hill, R., Lum, L., Martin, P., McGuffin, R., Sanders, J., Stewart, P., Sullivan, K., Witherspoon, R., Yee, G. & Thomas, E.D. (1986) Marrow transplantation for leukemia: methotrexate and cyclospor- ine compared with cyclosporine alone for prophylaxis of GVHD after marrow transplantation for leukemia. New England Journal of Medicine, 314, 729–735. Storb, R., Yu, C., Sanmeier, B.M., Mc Sweeney, P.A., Georges, G., Nash, R.A. & Woolfrey, A. (1999) Mixed hemopoietic chimerism after marrow allografts. Transplantation in the ambulatory care setting. Annals of the New York Academy of Sciences, 872, 372–375. Sudres, M., Norol, F., Trenado, A., Gregoire, S., Charlotte, F., Leva- cher, B., Lataillade, J.J., Bourin, P., Holy, X., Vernant, J.P., Klatz- mann, D. & Cohen, J.L. (2006) Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro but fail to prevent graft-versus-host disease in mice. Journal of Immunology, 176, 7761–7767. Sykes, M., Szot, G.L., Nguyen, P.L. & Pearson, D.A. (1995) Interleukin- 12 inhibits murine graft-versus-host disease. Blood, 86, 2429–2438. Sykes, M., Pearson, D.A., Taylor, P.A., Szot, G.L., Goldman, S.J. & Blazar, B.R. (1999) Dose and timing of interleukin (IL)-12 and timing and type of total-body irradiation: effects on graft-vs-host disease inhibition and toxicity of exogenous IL-12 in murine bone marrow transplant recipients. Biology of Blood and Marrow Trans- plantation, 5, 277–284. Teshima, T. & Ferrara, J.L. (2002a) Understanding the alloresponse: new approaches to graft-versus-host disease prevention. Seminars in Hematology, 39, 15–22. Teshima, T., Ordemann, R., Reddy, P., Gagin, S., Liu, C., Cooke, K.R. & Ferrara, J.L. (2002b) Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nature, 8, 575–581. Trenado, A., Sudres, M., Tang, Q., Maury, S., Charlotte, F., Gregoire, S., Bonyhadi, M., Klatzmann, D., Salomon, B.L. & Cohen, J.L. (2006) Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. Journal of Immunology, 176, 1266–1273. Tse, W.T., Beyer, W., Pendleton, J.D., D’Andrea, A. & Guinan, E.C. (2000) Bone marrow derived mesenchymal stem cells suppress T cell activation without inducing allogeneic anergy. Blood, 96, 1034a. Uberti, J.P., Ayash, L., Ratanatharathorn, V., Silver, S., Reynolds, C., Becker, M., Reddy, P., Cooke, K.R., Yanik, G., Whitfield, J., Jones, D., Hutchinson, R., Braun, T., Ferrara, J.L. & Levine, J.E. (2005) Pilot trial on the use of etanercept and methylprednisolone as pri- mary treatment for acute graft-versus-host disease. Biology of Blood and Marrow Transplantation, 11, 680–687. Van Lint, M.T., Uderzo, C., Locasciulli, A., Majolino, I., Scime, R., Locatelli, F., Georgiani, G., Arcese, W., Iori, A.P., Falda, M., Bosi, A., Miniero, R., Alessandrino, P., Dini, G., Rotoli, B. & Bacigalupo, A. (1998) Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood, 92, 2288–2293. Van Lint, M.T., Milone, G., Leotta, S., Uderzo, C., Scime, R., Dallorso, S., Locasciulli, A., Guidi, S., Mordini, N., Sica, S., Cudillo, L., Fagioli, F., Selleri, C., Bruno, B., Arcese, W. & Bacigalupo, A. (2006) Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood, 107, 4177–4181. Zander, A.R., Zabelina, T., Kroger, N., Renges, H., Kruger, W., Loliger, C., Durken, M., Stockschlader, M., de Wit, M., Wacker-Backhaus, G., Bielack, S., Jaburg, N., Russmann, B., Erttmann, R. & Kabisch, H. (1999) Use of a five-agent GvHD prevention regimen in recipients of unrelated donor marrow. Bone Marrow Transplantation, 23, 889–893. Zikos, P., van Lint, M.T., Frassoni, F., Lamparelli, T., Gualandi, F., Occhini, D., Mordini, N., Berisso, G., Bregante, S., De Stefano, F., Soracco, M., Vitale, V. & Bacigalupo, A. (1998) Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate. Blood, 91, 3503–3508. Review ª 2007 The Author 98 Journal Compilation ª 2007 Blackwell Publishing Ltd, British Journal of Haematology, 137, 87–98